Drug Profile
CIGB 300
Alternative Names: CIGB-300; IGBC-300; P15-TatLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology
- Developer Center for Genetic Engineering and Biotechnology; Elea; Heber Biotec
- Class Antineoplastics; Apoptosis regulatory proteins; Immunotherapies; Peptides
- Mechanism of Action Apoptosis stimulants; Casein kinase II inhibitors; Nucleophosmin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase II/III Condylomata acuminata
- Phase II Cervical cancer; Solid tumours
- Phase I/II Acute myeloid leukaemia; Leukaemia; Myelodysplastic syndromes
- No development reported Breast cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Breast-cancer in Cuba (IV)
- 30 Jul 2020 Center for Genetic Engineering and Biotechnology plans a phase I/II trial for COVID-19 infections (Combination therapy) in Cuba (IV) (RPCEC00000317)
- 21 Apr 2018 Preclinical trials in Breast cancer in Cuba (IV) prior to 21/04/2018